Unit Trust (UCITS compliant)

Legal & General Global Health & Pharmaceuticals Index Trust

Fund facts

Fund size
£625.7m
Base currency
GBP
Launch date
1 Nov 2000
Domicile
UK
Share class launch

Statistics

Historical yield
1.3%

As at 31 Aug 2020

Fund aim

The objective of the Fund is to provide growth by tracking the capital performance of the FTSE World Index - Health Care, the “Index”. This objective is after the deduction of charges and taxation.

Benchmark

FTSE World - Health Care Index

  • What does it invest in? Invests in the shares of global companies engaged in healthcare, pharmaceutical and biotechnology activities, as represented by the Index.
  • How does it invest? Passively managed, aiming to replicate the performance of the Index.

Fund updates

Performance

Source: Lipper

Performance (%)
Select period:
Change

    Performance summary (%)

    As at 31 Aug 2020

    CumulativeFundBenchmark
    1 month0.370.12
    6 months14.1511.85
    Year to date6.486.67
    3 years34.4035.73
    5 years73.7581.59
    Since launch--
    AnnualisedFundBenchmark
    1 year11.5011.61
    3 years10.3510.71
    5 years11.6712.66
    Since launch--

    As at 30 Jun 2020

    CumulativeFundBenchmark
    Quarterly14.5615.02
    Year to date7.468.90
    3 years37.2741.73
    5 years76.4183.89
    Since launch--
    AnnualisedFundBenchmark
    1 year16.4817.80
    3 years11.1312.32
    5 years12.0112.94
    Since launch--
    Rolling 12-month performance
    Calendar year performance
    Monthly performance
    Annualised performance

    Rolling 12-month performance to last quarter end (%)

    12 months to 30 June 2016 2017 2018 2019 2020
    Fund12.0514.694.5412.6916.53
    Benchmark14.6413.185.0614.4717.86

    Calendar year performance (%)

    2015 2016 2017 2018 2019
    Fund12.2612.2910.027.3718.83
    Benchmark13.8312.5210.799.8718.19

    Monthly performance (%)

    Annualised performance (%)

    1 year3 years5 yearsSince launch
    Fund11.5010.3511.67-
    Benchmark11.6110.7112.66-

    Annualised performance (%)

    1 year3 years5 yearsSince launch
    Fund16.4811.1312.01-
    Benchmark17.8012.3212.94-

    Performance for the C Acc unit class in GBP, launched on 22 February 2019. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.

    Past performance is not a guide to the future.

    Performance for the C Inc unit class in GBP, launched on 22 February 2019. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.

    Past performance is not a guide to the future.

    Performance for the F Acc unit class in GBP, launched on 20 December 2012. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.

    Past performance is not a guide to the future.

    Performance for the F Inc unit class in GBP, launched on 20 December 2012. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.

    Past performance is not a guide to the future.

    Performance for the I Acc unit class in GBP, launched on 26 August 2005. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.

    Past performance is not a guide to the future.

    Performance for the I Inc unit class in GBP, launched on 26 August 2005. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.

    Past performance is not a guide to the future.

    Performance for the R Acc unit class in GBP, launched on 01 November 2000. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.

    Past performance is not a guide to the future.

    Performance for the R Inc unit class in GBP, launched on 01 November 2000. Source: Lipper. Performance assumes all fund charges have been taken and that all income generated by the investments, after deduction of tax, remains in the fund. Please note, the benchmark is priced at the close whereas the fund is priced earlier. This can lead to artificially high tracking difference. Please see the fact sheet for gross tracking difference with both fund and index on a closed-price basis.

    Past performance is not a guide to the future.

    Portfolio

    As at 31 Aug 2020. All data source LGIM unless otherwise stated. Totals may not sum due to rounding. In order to minimise transaction costs, the Fund will not always own all the assets that constitute the index and on occasion it will own assets that are not in the index.

    Sector (%)

    Health Care100.0

    Market capitalisation (%)

    Large87.9
    Mid12.1
    Top 10 holdings37.6
    Rest of portfolio62.4
    No. of holdings in fund176
    No. of holdings in index176

    Top 10 holdings (%)

    Johnson & Johnson6.8
    Unitedhealth Group Inc5.0
    Roche4.1
    Merck & Co. Inc.3.6
    Pfizer Inc3.6
    Abbott Laboratories3.3
    Novartis3.1
    Abbvie Inc2.8
    Thermo Fisher Scientific2.8
    Amgen Inc2.5

    Country (%)

    United States64.1
    Switzerland9.1
    Japan7.3
    United Kingdom4.6
    Denmark3.2
    France3.1
    Germany2.3
    Australia2.2
    Netherlands0.9
    Other3.2

    Management Team

    The Index Fund Management team comprises 25 fund managers, supported by two analysts. Management oversight is provided by the Global Head of Index Funds. The team has average industry experience of 15 years, of which seven years has been at LGIM, and is focused on achieving the equally important objectives of close tracking and maximising returns.

    LGIMIndex Fund Management Team

    Literature

    Income

    Latest dividends

    The latest dividends are shown below. The historic level of income generated by this fund may go down as well up and will vary over time.

    of

    Dividend history

    Total dividends paid in each financial year of the fund.

    Prices

    Name
    I GBP Acc
    Bid price
    99.34p
    Offer price
    99.52p
    Absolute change
    -0.0061
    Currency
    GBP
    Price time
    15:00 UK time
    Name
    I GBP Inc
    Bid price
    78.17p
    Offer price
    78.31p
    Absolute change
    -0.0048
    Currency
    GBP
    Price time
    15:00 UK time
    Name
    R GBP Acc
    Bid price
    89.42p
    Offer price
    89.58p
    Absolute change
    -0.0055
    Currency
    GBP
    Price time
    15:00 UK time
    Name
    R GBP Inc
    Bid price
    77.84p
    Offer price
    77.98p
    Absolute change
    -0.0048
    Currency
    GBP
    Price time
    15:00 UK time
    Name
    F GBP Acc
    Bid price
    93.42p
    Offer price
    93.58p
    Absolute change
    -0.0057
    Currency
    GBP
    Price time
    15:00 UK time
    Name
    F GBP Inc
    Bid price
    78.20p
    Offer price
    78.33p
    Absolute change
    -0.0048
    Currency
    GBP
    Price time
    15:00 UK time
    Name
    C GBP Acc
    Bid price
    60.82p
    Offer price
    60.92p
    Absolute change
    -0.0037
    Currency
    GBP
    Price time
    15:00 UK time
    Name
    C GBP Inc
    Bid price
    59.98p
    Offer price
    60.09p
    Absolute change
    -0.0037
    Currency
    GBP
    Price time
    15:00 UK time

    Further details

    Costs

    Price basis
    Dual
    Initial charge
    0.00%
    Ongoing charges figure
    0.31%
    Bid / Offer spread
    0.19%

    Codes

    ISIN
    GB00B0CNH387
    SEDOL
    B0CNH38
    Bloomberg
    LEGGHIA
    MEX
    LGHPTA

    Dealing information

    Valuation frequencyDaily, 3pm (UK time)
    Dealing frequencyDaily
    Settlement periodT+4

    Country registration

    This share class is registered for sale in the following countries:

    For valuations and account queries contact:

    Legal & General (Unit Trust Managers) Limited
    PO Box 6080
    Wolverhampton
    WV1 9RB
    Tel : 0370 050 0955
    Email: [email protected]

    Legal & General ICAV
    LGIM Liquidity Funds Plc

    Northern Trust International Fund Administration Services (Ireland) Limited
    City East Plaza - Block A
    Towlerton
    Ballysimon Road
    Limerick
    Ireland
    V94 X2N9
    Fax: +353 1 434 5293
    Telephone: +353 1 434 5080
    Email: [email protected]

    Legal & General SICAV
    Northern Trust Global Services SE
    6 rue Lou Hemmer
    L-1748 Senningerberg
    Grand-Duché de Luxembourg
    Facsimile: +352 276 222 150
    Telephone: +352 276 222 514
    Email: [email protected]

    Key risks

    The value of an investment and any income taken from it is not guaranteed and can go down as well as up, you may not get back the amount you originally invested.

    Past performance is no guarantee of future results.

    The return from this fund is dependent on relatively few individual investments. This means that a fall in the value of an individual investment can have a major impact on the overall performance of the fund.

    Most of the fund holds investments from a particular market sector, that of health, pharmaceuticals and biotechnology. Funds like this can be more volatile than funds that invest across many market sectors. This is because the value of the fund can go up and down more often and by larger amounts than funds that are spread more widely, especially in the short term.

    The fund could lose money if any institution providing services such as acting as counterparty to derivatives or other instruments, becomes unwilling or unable to meet its obligations to the fund.

    Derivatives are highly sensitive to changes in the value of the asset on which they are based and can increase the size of losses and gains.

    The fund may have underlying investments that are valued in currencies that are different from sterling (British pounds). Exchange rate fluctuations will impact the value of your investment. Currency hedging techniques may be applied to reduce this impact but may not entirely eliminate it.

    Important information

    This information is intended for investment professionals only and is for information purposes only. It should not be distributed without our permission.

    No investment decisions should be made without first reviewing the key investor information document and prospectus (and any supplements thereto) of the relevant product which includes information on certain risks associated with an investment.

    Unless otherwise agreed in writing, the Information on this website (a) is for information purposes only and we are not soliciting any action based on it, and (b) is not a recommendation to buy or sell securities or pursue a particular investment strategy; and (c) is not investment, legal, regulatory or tax advice. Any trading or investment decisions taken by you should be based on your own analysis and judgment (and/or that of your professional advisers) and not in reliance on us or the Information.

    This information is only directed at investors resident in jurisdictions where each fund is registered for sale. It is not an offer or invitation to persons outside of those jurisdictions. We reserve the right to reject any applications from outside of such jurisdictions.

    All information detailed on this website is current at the time of publication and may be changed in the future.

    Source and third party data

    Source: Unless otherwise indicated all data contained on this website is sourced from Legal & General Investment Management Limited.

    Where this document contains third party data ('Third Party Data’), we cannot guarantee the accuracy, completeness or reliability of such Third Party Data and accept no responsibility or liability whatsoever in respect of such Third Party Data

    Issuer

    Issued by LGIM Managers (Europe) Limited as management company for this fund. Registered in Ireland No. 609677. Registered Office: 33/34 Sir John Rogerson’s Quay, Dublin, 2, Ireland. Authorised and Regulated by the Central Bank of Ireland No. C173733.

    Legal & General Investment Management Limited has been appointed as the discretionary investment manager for these Funds and is Registered in England and Wales No. 02091894. Registered Office: One Coleman Street, London, EC2R 5AA, United Kingdom. Authorised and regulated by the Financial Conduct Authority, No. 119272.

    Index disclaimer

    Source: London Stock Exchange Group plc and its group undertakings (collectively, the “LSE Group”). © LSE Group 2020. FTSE Russell is a trading name of certain of the LSE Group companies. “FTSE®” is a trade mark of the relevant LSE Group companies and is used by any other LSE Group company under license. All rights in the FTSE Russell indexes or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indexes or data and no party may rely on any indexes or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company’s express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication.